NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Viromed AG's Strategic Focus on Cold Plasma Technology and Respiratory Disease Research
TL;DR
Viromed Medical AG's PulmoPlas® system offers a unique technological advantage in treating respiratory infections, positioning the company as a leader in the global MedTech market.
Viromed develops cold plasma devices like ViroCAP® and PulmoPlas® through research partnerships with institutions such as MHH and HZI, focusing on clinical applications and regulatory approval.
Viromed's innovations in cold plasma technology aim to improve treatments for severe respiratory diseases, potentially enhancing global health outcomes and fighting pathogenic germs.
Viromed's PulmoPlas® is a globally unique cold plasma system for respiratory infections, developed with top scientific partners, with results expected to be published soon.
Found this article helpful?
Share it with your network and spread the knowledge!
Viromed's strategic update confirms its continued focus on sustainable, technology-driven growth in the international MedTech market, specifically concentrating on developing innovative medical devices and conducting translational research in severe respiratory diseases, particularly ventilator-associated pneumonia (VAP).
Viromed has developed ViroCAP® - an innovative cold plasma device for medical wound healing, and PulmoPlas® - a globally unique cold plasma system for applications in pneumology and respiratory tract infections.
PulmoPlas® is considered a next-generation technological platform that forms the basis for future scaling potential across multiple medical indication areas, making it central to Viromed's growth strategy.
Viromed has established a high-performance scientific consortium consisting of Hannover Medical School (MHH), the Helmholtz Centre for Infection Research (HZI) in Braunschweig, and the Leibniz Institute in Jena, bringing together international top-level expertise in infectiology, pneumology, and translational research.
The comprehensive publication of the results by MHH and HZI is expected at the end of January 2026.
Viromed works closely with Relyon Plasma (a subsidiary of TDK) for technological development and has established international partnerships in Europe, Korea, and Turkey to support future market entry and underscore the global relevance of their technology.
Due to longer innovation cycles resulting from their strategic focus on research, development, and establishing international market structures, Viromed deliberately refrains from communicating short-term operational interim updates, instead reporting substantial and relevant milestones for long-term, sustainable corporate development.
Viromed has successfully overcome the new, stringent regulatory hurdles for the approval of ViroCAP® over the past 18 months, and market acceptance and demand for ViroCAP® are already very high.
According to its own assessment, Viromed will play a significant role in the global fight against pathogenic germs in the coming years, particularly with PulmoPlas®, and has the potential to significantly shape future therapeutic approaches for severe respiratory infections.
Viromed's corporate strategy is geared toward long-term value generation, with research and development programs consistently aligned with medical benefit, clinical relevance, and sustainable market potential, focusing on substantial milestones rather than short-term updates.
Curated from NewMediaWire
